The Corporate Transparency Act (the “CTA”) became effective January 1, 2024 and it applies to a large range of private companies. The CTA is part of the Anti-Money Laundering Act of 2020, with the purpose to combat money laundering and other illicit activities through anonymously owned entities. The CTA applies both to newly formed and already existing entities, and it imposes obligations on covered entities to report the identity of their significant beneficial owners and other people exercising control over the entity (along with copies of a driver’s license or passport for each covered individual). Companies, on an ongoing basis, must also report any changes to such information within 30 days of any change. This webinar will explain which entities are covered by the CTA, who has obligations to report the information, what information must be reported and how to protect the confidentiality of this information.

Join us for an insightful webinar on doing business in Canada and the state of the BC startup economy. Co-organized by BC Trade and Invest, the Alliance of Angels, and the Consulate General of Canada in Seattle. This session is designed for investors and entrepreneurs looking to explore and understand the dynamics of entering and thriving in the Canadian market, particularly in British Columbia.

Join Lowell Ricklefs, a SaaS veteran with experience selling/buying more than 30 businesses for this webinar on angel backed exits. Lowell will cover: What metrics matter What drives valuation What companies are truly sellable and what are the keys Strategic or financial buyer - pros and cons? How about a tax-free gain - QSBS? What's a waterfall? Cap table % vs % of payout Common deal structure components

Whether you are ready to start now or planning for the future this interactive session is designed to provide a framework for thinking about angel investing, how to make your first deal, and how to engage as an ongoing investor. Join AoA member Lowell Ricklefs and learn about: [1] How to think about the different stages of start-ups and build a portfolio [2] How many deals you need to be in, liquidity of your investments, timing, and deal flow [3] Due diligence: the basics of evaluating start-ups [4] How deals are structured and legal basics

The complexities and nuances of life science startup companies can often be a black box to traditional tech investors. Not only do their life cycles tend to be longer, but the specific domain expertise and regulatory hurdles that are required to navigate the waters have often been barriers for investors not familiar with the industry. Come learn about the primary factors that differentiate life science startups from traditional tech investment opportunities from IntuitiveX, the leading life science consultancy and incubator based in Seattle.

Join Hugh Matsubayashi and Pam Jacobson of K&L Gates for an interactive session on what entrepreneurs & investors need to know about patents & intellectual property, including a discussion on how to identify and protect startups’ technology innovations to secure value.